Investor Relations
Jan 07, 2019
OPKO Health Appoints Jon R. Cohen, M.D. Executive Chairman of BioReference Laboratories MORE >>
Dec 27, 2018
OPKO Health and OPKO's CEO and Chairman, Dr. Phillip Frost, Announce Proposed Resolution of SEC Action MORE >>
Nov 09, 2018
OPKO Health Reports Third Quarter 2018 Financial Results MORE >>
Nov 08, 2018
BioReference Laboratories Named as Preferred Laboratory with Horizon Healthcare Services MORE >>

Press Releases

All Releases
OPKO Health to Present at UBS 2007 Global Life Sciences Conference
Sep 18, 2007
MIAMI, Sept. 18 /PRNewswire-FirstCall/ -- OPKO Health Inc. (Amex: OPK - News) today announced that it will present at the UBS 2007 Global Life Sciences Conference on Tuesday, September 25, 2007 at 11:30 am EDT. The conference will be held at the Grand Hyatt New York in New York City.
OPKO Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Aug 30, 2007
Groundbreaking Trial Is Designed to Compare Efficacy of Bevasiranib Administered Every 8 Weeks or 12 Weeks with Genentech's Lucentis® Administered Every 4 Weeks
OPKO Health, Inc. Announces Early Termination of Hart-Scott-Rodino Period for Proposed Purchase of Shares by Dr. Phillip Frost
Jul 12, 2007
Opko Health, Inc. Announces Early Termination of Hart-Scott-Rodino Period for Proposed Purchase of Shares by Dr. Phillip Frost MIAMI, FL– July 12, 2007– Opko Health Inc. (AMEX: OPK) today announced that that the U.S. Department of Justice has granted early termination of the waiting
OPKO Health Initiates Phase 3 Trial of Bevasiranib for the Treatment of AMD
Jul 11, 2007
-- Trial Designed to Compare Efficacy of Bevasiranib Administered Every 8 Weeks or 12 Weeks with Lucentis® Administered Every 4 Weeks --

-- Represents First-Ever Phase 3 Pivotal Trial of an RNAi Therapeutic --
Exegenics Changes Name to OPKO Health and Receives Approval for Its Shares to Trade on the American Stock Exchange Under the Symbol OPK
Jun 08, 2007
EXEGENICS CHANGES NAME TO OPKO HEALTH AND RECEIVES APPROVAL FOR ITS SHARES TO TRADE ON THE AMERICAN STOCK EXCHANGE UNDER THE SYMBOL OPK MIAMI, FL - June 8, 2007 - eXegenics, Inc. (OTC BB: EXEG) today announced that it has completed its name change to Opko Health Inc.
OPKO Health, Inc. to Acquire Diagnostic Imaging Firm
Jun 01, 2007
Hires Industry Veteran as Executive Vice President of Instrumentation
Exegenics, Inc. Announces Senior Management Appointments; Company Intends to Change its Name to OPKO Health
May 04, 2007
Exegenics, Inc. Announces Senior Management Appointments; Company Intends to Change its Name to OPKO Health MIAMI, FL?May 4, 2007? eXegenics, Inc., (OTC BB: EXEG), doing business as Opko Health, today announced appointment of its senior management team. Dr.
Acuity Pharmaceuticals and Froptix Corporation Agree to Mergers with Public Shell; New Company to Develop and Market Drugs for Disorders of the Eye
Mar 27, 2007
Combined Company to be Re-Named Opko Corporation
Displaying 361 - 368 of 368